{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:57:35Z","timestamp":1793692655669,"version":"4.5.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T00:00:00Z","timestamp":1519603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T00:00:00Z","timestamp":1519603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Polycystic kidney disease (PKD) is a common genetic disorder characterized by the growth of fluid-filled cysts in the kidneys. Several studies reported that the serine-threonine kinase Lkb1 is dysregulated in PKD. Here we show that genetic ablation of Lkb1 in the embryonic ureteric bud has no effects on tubule formation, maintenance, or growth. However, co-ablation of Lkb1 and Tsc1, an mTOR repressor, results in an early developing, aggressive form of PKD. We find that both loss of Lkb1 and loss of Pkd1 render cells dependent on glutamine for growth. Metabolomics analysis suggests that Lkb1 mutant kidneys require glutamine for non-essential amino acid and glutathione metabolism. Inhibition of glutamine metabolism in both Lkb1\/Tsc1 and Pkd1 mutant mice significantly reduces cyst progression. Thus, we identify a role for Lkb1 in glutamine metabolism within the kidney epithelia and suggest that drugs targeting glutamine metabolism may help reduce cyst number and\/or size in PKD.<\/jats:p>","DOI":"10.1038\/s41467-018-03036-y","type":"journal-article","created":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T16:19:01Z","timestamp":1519143541000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Lkb1 deficiency confers glutamine dependency in polycystic kidney disease"],"prefix":"10.1038","volume":"9","author":[{"given":"Ebony M.","family":"Flowers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Sudderth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Zacharias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenda","family":"Mernaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Zent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph J.","family":"DeBerardinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,26]]},"reference":[{"key":"3036_CR1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1681\/ASN.V96937","volume":"9","author":"K Ramasubbu","year":"1998","unstructured":"Ramasubbu, K., Gretz, N. & Bachmann, S. Increased epithelial cell proliferation and abnormal extracellular matrix in rat polycystic kidney disease. J. Am. Soc. Nephrol. 9, 937\u2013945 (1998).","journal-title":"J. Am. Soc. Nephrol."},{"key":"3036_CR2","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1681\/ASN.V1171179","volume":"11","author":"K Hanaoka","year":"2000","unstructured":"Hanaoka, K. & Guggino, W. B. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J. Am. Soc. Nephrol. 11, 1179\u20131187 (2000).","journal-title":"J. Am. Soc. Nephrol."},{"key":"3036_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/ng1701","volume":"38","author":"E Fischer","year":"2006","unstructured":"Fischer, E. et al. Defective planar cell polarity in polycystic kidney disease. Nat. Genet. 38, 21\u201323 (2006).","journal-title":"Nat. Genet."},{"key":"3036_CR4","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1681\/ASN.2010010127","volume":"21","author":"A Luyten","year":"2010","unstructured":"Luyten, A. et al. Aberrant regulation of planar cell polarity in polycystic kidney disease. J. Am. Soc. Nephrol. 21, 1521\u20131532 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"3036_CR5","doi-asserted-by":"publisher","first-page":"F551","DOI":"10.1152\/ajprenal.00218.2014","volume":"307","author":"M Beck Gooz","year":"2014","unstructured":"Beck Gooz, M. et al. ADAM17 promotes proliferation of collecting duct kidney epithelial cells through ERK activation and increased glycolysis in polycystic kidney disease. Am. J. Physiol. Physiol. 307, F551\u2013F559 (2014).","journal-title":"Am. J. Physiol. Physiol."},{"key":"3036_CR6","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nm.3092","volume":"19","author":"I Rowe","year":"2013","unstructured":"Rowe, I. et al. Defective glucose metabolism in polycystic kidney disease identifies a novel therapeutic paradigm. Nat. Med. 19, 488\u2013493 (2013).","journal-title":"Nat. Med."},{"key":"3036_CR7","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1097\/01.ASN.0000029587.47950.25","volume":"13","author":"BK Yoder","year":"2002","unstructured":"Yoder, B. K., Hou, X. & Guay-Woodford, L. M. The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J. Am. Soc. Nephrol.\n                            13, 2508\u20132516 (2002).","journal-title":"J. Am. Soc. Nephrol."},{"key":"3036_CR8","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. New Engl. J. Med. 367, 2407\u20132418 (2012).","journal-title":"New Engl. J. Med."},{"key":"3036_CR9","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","volume":"38","author":"PB Watkins","year":"2015","unstructured":"Watkins, P. B. et al. Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf.\n                            38, 1103\u20131113 (2015).","journal-title":"Drug Saf."},{"key":"3036_CR10","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1158\/0008-5472.613.65.2","volume":"65","author":"Rh Xu","year":"2005","unstructured":"Xu, R.-h.et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res.\n                            65, 613\u2013621 (2005).","journal-title":"Cancer Res."},{"key":"3036_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1042\/bj20031541","volume":"378","author":"A ISIDORO","year":"2004","unstructured":"ISIDORO, A. et al. Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochem. J. 378, 17\u201320 (2004).","journal-title":"Biochem. J."},{"key":"3036_CR12","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1158\/1535-7163.MCT-12-0131","volume":"11","author":"Y Liu","year":"2012","unstructured":"Liu, Y. et al. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol. Cancer Ther.\n                            11, 1672\u20131682 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"3036_CR13","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.cell.2008.08.021","volume":"134","author":"PP Hsu","year":"2008","unstructured":"Hsu, P. P. & Sabatini, D. M. Cancer cell metabolism: Warburg and beyond. Cell 134, 703\u2013707 (2008).","journal-title":"Cell"},{"key":"3036_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cmet.2007.10.002","volume":"7","author":"RJ DeBerardinis","year":"2008","unstructured":"DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G. & Thompson, C. B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell. Metab.\n                            7, 11\u201320 (2008).","journal-title":"Cell. Metab."},{"key":"3036_CR15","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM194912292412601","volume":"241","author":"H Jeghers","year":"1949","unstructured":"Jeghers, H., McKusick, V. A. & Katz, K. H. Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits. New Engl. J. Med.\n                            241, 1031\u20131036 (1949).","journal-title":"New Engl. J. Med."},{"key":"3036_CR16","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1086\/302159","volume":"63","author":"H Mehenni","year":"1998","unstructured":"Mehenni, H. et al. Loss of LKB1 kinase activity in Peutz-Jeghers Syndrome, and evidence for allelic and locus heterogeneity. Am. J. Human Genet. 63, 1641\u20131650 (1998).","journal-title":"Am. J. Human Genet."},{"key":"3036_CR17","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.febslet.2011.01.019","volume":"585","author":"BorisY Shorning","year":"2011","unstructured":"Boris Y. & Shorning, A.R.C. Lkb1 loss of function studied in vivo. FEBS Lett. 585, 958\u2013966 (2011).","journal-title":"FEBS Lett."},{"key":"3036_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cmet.2012.12.001","volume":"17","author":"B Faubert","year":"2013","unstructured":"Faubert, B. et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 17, 113\u2013124 (2013).","journal-title":"Cell Metab."},{"key":"3036_CR19","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1073\/pnas.1312570111","volume":"111","author":"B Faubert","year":"2014","unstructured":"Faubert, B. et al. Loss of the tumor suppressor Lkb1 promotes metabolic reprogramming of cancer cells via HIF-1alpha. Proc. Natl. Acad. Sci. USA 111, 2554\u20132559 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3036_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrc2676","volume":"9","author":"DBSARJ Shaw","year":"2009","unstructured":"Shaw, D. B. S. A. R. J. TheLkb1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer 9, 563\u2013575 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"3036_CR21","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.bbrc.2006.10.056","volume":"351","author":"KI Kenta Imai","year":"2006","unstructured":"Kenta Imai, K. I., Ikegami, Y., Awata, T. & Katayama, S. Lkb1, an upstream AMPK kinase, regulates glucose and lipid metabolism in cultured liver and muscle cells. Biochem. Biophys. Res. Commun.\n                            351, 595\u2013601 (2006).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"3036_CR22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1152\/physrev.00026.2008","volume":"89","author":"M Jansen","year":"2009","unstructured":"Jansen, M., ten Klooster, J. P., Offerhaus, G. J. & Clevers, H. LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism. Physiol. Rev. 89, 777\u2013798 (2009).","journal-title":"Physiol. Rev."},{"key":"3036_CR23","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/ncb2117","volume":"12","author":"C Boehlke","year":"2010","unstructured":"Boehlke, C. et al. Primary cilia regulate mTORC1 activity and cell size through Lkb1. Nat. Cell Biol. 12, 1115\u20131122 (2010).","journal-title":"Nat. Cell Biol."},{"key":"3036_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2004.06.007","volume":"6","author":"RJ Shaw","year":"2004","unstructured":"Shaw, R. J. et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6, 91\u201399 (2004).","journal-title":"Cancer Cell"},{"key":"3036_CR25","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1038\/onc.2012.431","volume":"32","author":"HB Nguyen","year":"2013","unstructured":"Nguyen, H. B., Babcock, J. T., Wells, C. D. & Quilliam, L. A. LKB1 tumor suppressor regulates AMP kinase\/mTOR-independent cell growth and proliferation via the phosphorylation of Yap. Oncogene 32, 4100\u20134109 (2013).","journal-title":"Oncogene"},{"key":"3036_CR26","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1073\/pnas.0308061100","volume":"101","author":"R Shaw","year":"2003","unstructured":"Shaw, R. et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. USA 101, 3329\u20133335 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3036_CR27","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1681\/ASN.2014121181","volume":"27","author":"SH Han","year":"2016","unstructured":"Han, S. H. et al. Deletion of Lkb1 in Renal Tubular Epithelial Cells Leads to CKD by Altering Metabolism. J. Am. Soc. Nephrol. 27, 439\u2013453 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"3036_CR28","doi-asserted-by":"publisher","first-page":"e0146654","DOI":"10.1371\/journal.pone.0146654","volume":"11","author":"M Riwanto","year":"2016","unstructured":"RiwantoM., KapoorS., RodriguezD., EdenhoferI., SegererS. & W\u00fcthrichR. P. Inhibition of aerobic glycolysis attenuates disease progression in polycystic kidney disease. PLoS ONE\n                            11, e0146654 (2016).","journal-title":"PLoS ONE"},{"key":"3036_CR29","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1158\/1078-0432.CCR-12-2334","volume":"19","author":"M Hassanein","year":"2012","unstructured":"Hassanein, M. et al. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin. Cancer Res. 19, 560\u2013570 (2012).","journal-title":"Clin. Cancer Res."},{"key":"3036_CR30","first-page":"370","volume":"1826","author":"JQ Chen","year":"2012","unstructured":"Chen, J.-Q. & RussoJ. Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppresors in cancer cells. Biochim. Biophys. Acta 1826, 370\u2013384 (2012).","journal-title":"Biochim. Biophys. Acta"},{"key":"3036_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cbf.1003","volume":"21","author":"P Newsholme","year":"2003","unstructured":"Newsholme, P., Procopio, J., Lima, M. M. & Pithon-Curi, T. C. & CuriR.. Glutamine and glutamate\u2014their central role in cell metabolism and function. Cell. Biochem. Funct. 21, 1\u20139 (2003).","journal-title":"Cell. Biochem. Funct."},{"key":"3036_CR32","doi-asserted-by":"publisher","first-page":"18782","DOI":"10.1073\/pnas.0810199105","volume":"105","author":"DR Wise","year":"2008","unstructured":"Wise, D. R. et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. USA 105, 18782\u201318787 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3036_CR33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature12040","volume":"496","author":"J Son","year":"2013","unstructured":"Son, J. et al. Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway. Nature 496, 101\u2013105 (2013).","journal-title":"Nature"},{"key":"3036_CR34","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nature07823","volume":"458","author":"P Gao","year":"2009","unstructured":"Gao, P. et al. c-Myc suppression of miR-23a\/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458, 762\u2013765 (2009).","journal-title":"Nature"},{"key":"3036_CR35","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.cell.2013.04.023","volume":"153","author":"A Csibi","year":"2013","unstructured":"Csibi, A. et al. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 153, 840\u2013854 (2013).","journal-title":"Cell"},{"key":"3036_CR36","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1002\/ijc.29535","volume":"137","author":"M Hassanein","year":"2015","unstructured":"Hassanein, M. et al. Targeting SLC1A5-mediated glutamine dependence in non-small cell lung cancer. Int. J. Cancer 137, 1587\u20131597 (2015).","journal-title":"Int. J. Cancer"},{"key":"3036_CR37","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1172\/JCI75836","volume":"125","author":"Y Xiang","year":"2015","unstructured":"Xiang, Y. et al. Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J. Clin. Invest. 125, 2293\u20132306 (2015).","journal-title":"J. Clin. Invest."},{"key":"3036_CR38","doi-asserted-by":"publisher","first-page":"e115144","DOI":"10.1371\/journal.pone.0115144","volume":"9","author":"DB Ulanet","year":"2014","unstructured":"Ulanet, D. B. et al. Mesenchymal phenotype predisposes lung cancer cells to impaired proliferation and redox stress in response to glutaminase inhibition. PLoS ONE 9, e115144 (2014).","journal-title":"PLoS ONE"},{"key":"3036_CR39","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/ng.2715","volume":"45","author":"M Ma","year":"2013","unstructured":"Ma, M., Tian, X., Igarashi, P., Pazour, G. J. & Somlo, S. Loss of cilia suppresses cyst growth in genetic models of autosomal dominant polycystic kidney disease. Nat. Genet. 45, 1004\u20131012 (2013).","journal-title":"Nat. Genet."},{"key":"3036_CR40","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1681\/ASN.2012020154","volume":"24","author":"N Sharma","year":"2013","unstructured":"Sharma, N. et al. Proximal tubule proliferation is insufficient to induce rapid cyst formation after cilia disruption. J. Am. Soc. Nephrol. 24, 456\u2013464 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"3036_CR41","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/onc.2009.358","volume":"29","author":"RJ DeBerardinis","year":"2010","unstructured":"DeBerardinis, R. J. & Cheng, T. Q\u2019s next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29, 313\u2013324 (2010).","journal-title":"Oncogene"},{"key":"3036_CR42","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/msb.2011.56","volume":"7","author":"D Gaglio","year":"2011","unstructured":"Gaglio, D. et al. Oncogenic K\u2010Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol. Syst. Biol. 7, 523 (2011).","journal-title":"Mol. Syst. Biol."},{"key":"3036_CR43","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1038\/nm1675","volume":"13","author":"K Piontek","year":"2007","unstructured":"Piontek, K., Menezes, L. F., Garcia-Gonzalez, M. A., Huso, D. L. & Germino, G. G.A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. Nat. Med. 13, 1490\u20131495 (2007).","journal-title":"Nat. Med."},{"key":"3036_CR44","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nm.3092","volume":"19","author":"I Rowe","year":"2013","unstructured":"Rowe, I. et al. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat. Med. 19, 488\u2013493 (2013).","journal-title":"Nat. Med."},{"key":"3036_CR45","doi-asserted-by":"publisher","first-page":"F492","DOI":"10.1152\/ajprenal.00238.2015","volume":"309","author":"VJ Hwang","year":"2015","unstructured":"Hwang, V. J. et al. The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate. Am. J. Physiol. Ren. Physiol. 309, F492\u2013F498 (2015).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"3036_CR46","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1242\/dev.129.22.5301","volume":"129","author":"J Yu","year":"2002","unstructured":"Yu, J., Carroll, T. J. & McMahon, A. P. Sonic hedgehog regulates proliferation and differentiation of mesenchymal cells in the mouse metanephric kidney. Development 129, 5301\u20135312 (2002).","journal-title":"Development"},{"key":"3036_CR47","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nature01045","volume":"419","author":"N Bardeesy","year":"2002","unstructured":"Bardeesy, N. et al. Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature 419, 162\u2013167 (2002).","journal-title":"Nature"},{"key":"3036_CR48","first-page":"F356","volume":"307","author":"SS Williams","year":"2014","unstructured":"Williams, S. S. et al. Tissue-specific regulation of the mouse Pkhd1 (ARPKD) gene promoter. Am. J. Physiol. \u2014Ren. Physiol. 307, F356\u2013F368 (2014).","journal-title":"Am. J. Physiol."},{"key":"3036_CR49","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/hmg\/ddi039","volume":"14","author":"L Meikle","year":"2005","unstructured":"Meikle, L. et al. A mouse model of cardiac rhabdomyoma generated by loss of Tsc1 in ventricular myocytes. Hum. Mol. Genet. 14, 429\u2013435 (2005).","journal-title":"Hum. Mol. Genet."},{"key":"3036_CR50","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1093\/hmg\/ddn039","volume":"17","author":"S Shibazaki","year":"2008","unstructured":"Shibazaki, S. et al. Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. Hum. Mol. Genet. 17, 1505\u20131516 (2008).","journal-title":"Hum. Mol. Genet."},{"key":"3036_CR51","doi-asserted-by":"crossref","unstructured":"Carroll, T. J., Park, J.-S., Hayashi, S., Majumdar, A. & McMahon, A.P. Wnt9b plays a central role in the regulation of mesenchymal to epithelial transitions underlying organogenesis of the mammalian urogenital system. Dev. Cell 9, 283\u2013292 (2005).","DOI":"10.1016\/j.devcel.2005.05.016"},{"key":"3036_CR52","doi-asserted-by":"crossref","unstructured":"Karner, C. M. et al. Canonical Wnt9b signaling balances progenitor cell expansion and differentiation during kidney development. Development 138, 1247\u20131257\u00a0(2011).\u00a0","DOI":"10.1242\/dev.057646"},{"key":"3036_CR53","first-page":"F1160","volume":"255","author":"RF Husted","year":"1988","unstructured":"Husted, R. F., Hayashi, M. & Stokes, J. B. Characteristics of papillary collecting duct cells in primary culture. Am. J. Physiol. 255, F1160\u2013F1169 (1988).","journal-title":"Am. J. Physiol."},{"key":"3036_CR54","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.celrep.2014.04.037","volume":"7","author":"AndrewnbspR Mullen","year":"2014","unstructured":"Mullen, Andrew R. et al. Oxidation of alpha-ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects. Cell Rep. 7, 1679\u20131690 (2014).","journal-title":"Cell Rep."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-03036-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-03036-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-03036-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T13:11:55Z","timestamp":1671541915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-03036-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,26]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["3036"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-03036-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,26]]},"assertion":[{"value":"17 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. DeBerardinis is a member of the scientific advisory board of Agios Therapeutics. The other authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"814"}}